about
Observations on comatose survivors of cardiopulmonary resuscitation with generalized myoclonus.Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.Definition of the single integration site of the pathogenicity locus in Clostridium difficile.Objective consensus from decision treesIntravascular lymphoma mimicking cerebral stroke: report of two cases.Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model.Neuroborreliosis Mimicking Leptomeningeal Carcinomatosis in a Patient With Breast Cancer: A Case ReportManagement der akuten Meningitis und Enzephalitis: ein klinischer Leitfaden.Nerve Ultrasound as a Decisive Tool in Nonsystemic Vasculitic Neuropathy: A Case ReportManagement of von hippel-lindau disease: an interdisciplinary review.Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC).Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile.Radiation-induced cavernoma after total body irradiation and haematopoietic stem cell transplantation in an adult patient suffering from acute myeloid leukaemia.Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis.High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.[Glioblastoma multiforme--new hope due to modern therapeutical approaches].AT-26CLINICAL MANAGEMENT AND OUTCOME OF HISTOLOGICALLY VERIFIED ADULT BRAINSTEM GLIOMAS IN SWITZERLAND: A RETROSPECTIVE ANALYSIS OF 21 PATIENTS.Nimustine (ACNU) plus teniposide (VM26) in recurrent glioblastoma.MGMT in primary and recurrent human glioblastomas after radiation and chemotherapy and comparison with p53 status and clinical outcome.Heart rate variability decreases after 3 months of sustained treatment with fingolimod.Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma.Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma.Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.External validation of a prognostic model estimating the survival of patients with recurrent high-grade gliomas after reirradiation.F-18 choline PET does not detect increased metabolism in F-18 fluoroethyltyrosine-negative low-grade gliomas.Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes.Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease.Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis.[Meningioma: management of the most common brain tumour].Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial.AT-59HIGH-DOSE MTX-BASED CHEMOTHERAPY FOR PRIMARY CNS LYMPHOMA: WITH OR WITHOUT WHOLE BRAIN RADIOTHERAPY? FINAL ANALYSIS OF G-PCNSL-SG-1.[Pain in the sole of the foot. Have you suspected its cause in the knee?]Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases[Nerve sonography of intraneural ganglia as cause painful peroneal palsies: a case series]Autonomic dysfunction in cancer cachexia coincides with large fiber polyneuropathy[Neurological complications in cancer patients]Leptomeningeal lymphomatosis from large granular lymphocyte leukaemiaFieber bei monoklonaler Gammopathie und Immunneuropathie – ein differenzialdiagnostischer Sple(e)n[A Rare Cause for Transient Aphasia after Conorary Angiography]
P50
Q24815511-E9504FE4-4D4C-478D-88C5-A0B9DF1E93ADQ33414998-8A2AD02E-A4DF-48CF-9650-92AA2E09BA6BQ34411605-EFDEA53B-23E6-42A0-B37E-EA542D4C7FF5Q34727909-811ED51D-A405-440F-BC94-8D0DA1D8BA17Q35574210-273DE9A3-DAAB-4563-B9CF-F8C68F046185Q35662578-6F91AC7A-12E4-43D7-A234-FB8D932FCB66Q35927613-071741AA-C6BD-4B6E-BE9B-AB39D3ABA445Q36315885-712DF3F6-BCED-4CC1-9895-8D47997E2B77Q37045811-5E480F9A-630A-422F-AA40-37A38E38AE31Q38297048-E6468F0C-26E4-4EB2-9F8C-133F696C299CQ38334960-E273C9CD-E6A4-4AD1-9071-601508DABEDDQ38347728-7A1213FA-8CF8-4976-BD0C-2E8D77938F8EQ40787425-F3D8B4F6-F65C-4F49-9E0D-CF4D35FB131BQ41438791-4153C33E-C24D-4471-AD72-7A63725D624AQ42849724-27DA5841-0B71-4C07-9AAE-AF6EFCEFE039Q43142057-AFC97695-1D34-491F-997C-558D14644DF3Q45745778-DA8D7D65-C4D1-4D59-90CD-9CAA8B4B5F05Q46121346-60646CE0-7CC5-45C2-8EAB-8D9D2A486C0EQ46901432-715C9AF3-76FF-4329-913F-7855FE9411C2Q47749135-7E108CE8-F171-467B-90B9-1F9BDBC27418Q48260300-6D6688AF-B248-45E3-B615-179C1455A4D7Q48309944-5A8A1B63-F860-425B-B859-07D2DA6E611FQ48418407-D12172B3-10BC-40E9-A3A7-2A06BAA32A37Q48447398-94E2AFE3-ED3A-44D1-8893-2811AB537D90Q48788398-7DFF94C5-9B62-455C-A854-7DD1A3B19C97Q50215033-6EB17237-BF48-4D05-A446-62CB09EBF4A4Q50794065-AF231CD9-D86D-464C-9F24-3BA5CCF6BB04Q51236198-8AEBBC43-66D9-40B0-A6D1-9FC94EF4882DQ51717385-E6C6BFA8-E430-417D-8281-1A373267D484Q53122187-2B251418-F857-4969-B8C1-2004F4246D02Q53830664-29360B92-E4D4-4E1B-8384-C51EB850506DQ55709969-E00F9E8D-7893-439F-9311-FA76E2991760Q84719403-E90A5CE0-3AB3-4018-B5BC-37567D18DAFBQ85322084-45E5EC39-DD17-40AD-80B8-307CFC66CABDQ86103980-72B511BE-F2A4-4149-A203-977E710A45D6Q87630503-B8CE9F28-0D66-4DB4-811A-B4C66FA2D867Q87637304-C7C09B68-F535-495A-8823-E57DCCB6E8D5Q87782481-835F42ED-4021-42C6-9170-8FF7A5B99104Q88048870-B6948DE1-89D4-4B6C-B789-4005EF8926E9Q88460437-DC9EC86A-5EC8-41E0-96F1-53AE5FF5E81B
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
T Hundsberger
@ast
T Hundsberger
@en
T Hundsberger
@es
T Hundsberger
@nl
type
label
T Hundsberger
@ast
T Hundsberger
@en
T Hundsberger
@es
T Hundsberger
@nl
prefLabel
T Hundsberger
@ast
T Hundsberger
@en
T Hundsberger
@es
T Hundsberger
@nl
P214
P106
P1153
6508277718
P214
P31
P496
0000-0002-4419-2767
P7859
viaf-42661344